Carrie C, Magné N, Burban-Provost P, et al. - Researchers provide updated results from the GETUG-AFU 16 trial—an open-label, multicentre, phase 3, randomised, controlled trial—wherein the effectiveness of radiotherapy plus androgen suppression vs radiotherapy alone was tested in men (aged ≥ 18 years) with histologically confirmed adenocarcinoma of the prostate, stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx as per TNM staging system, whose prostate-specific antigen (PSA) level rose from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL post-radical prostatectomy, without proof of clinical disease. The findings from the primary analysis were corroborated by the observed 120-month progression-free survival. A significant reduction in the risk of biochemical or clinical progression and mortality was observed in relation to salvage radiotherapy combined with short-term androgen suppression vs salvage radiotherapy alone. In patients exhibiting rising PSA levels following radical prostatectomy for prostate cancer, androgen suppression plus radiotherapy was confirmed as an effective salvage treatment.